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AbstrAct
The full British Thoracic Society Guideline for 
Bronchiectasis in Adults is published in Thorax. The 
following is a summary of the recommendations and good 
practice points. The sections referred to in the summary 
refer to the full guideline. The appendices are available in 
the full guideline.
IntroductIon
The full Guideline for Bronchiectasis in 
Adults is published in Thorax.1 The key 
features of the guideline are highlighted in 
a short article published to accompany the 
full guideline.2 The following is a summary 
of the recommendations and good prac-
tice points and includes all figures 1–5 and 
tables 1–7. The sections referred to in the 
summary refer to the full guideline.
Table 1 provides a summary of overall 
management.
bAckground
This guideline refers to the investigation 
and management of patients with symptoms 
of persistent or recurrent bronchial sepsis 
related to irreversibly damaged and dilated 
bronchi, namely clinical bronchiectasis. It 
does not cover the management of cystic 
fibrosis (CF), and for the purposes of the 
guideline, ‘bronchiectasis’ is synonymous 
with the term ‘non-CF bronchiectasis’. Like-
wise, it does not focus on traction bronchi-
ectasis secondary to other lung pathologies, 
particularly the interstitial lung diseases, as 
the bronchiectasis is commonly asympto-
matic.
For guidance on treatment for patients 
with non-tuberculous mycobacteria and 
bronchiectasis, please refer to the BTS 
Guideline on the management of non-tuber-
culous mycobacterial pulmonary disease.3
tArget AudIence for the guIdelIne
This guideline is aimed at all healthcare 
practitioners who are involved in the care 
of patients with bronchiectasis: this will 
include primary care clinicians (general 
practitioners, practice and district nurses) 
and hospital specialist teams in infectious 
disease, respiratory medicine (respiratory 
nurse specialists, respiratory physiothera-
pists, pharmacists, physicians and surgeons), 
microbiologists, and radiologists.
AreAs covered by the guIdelIne
This guideline covers adults. The following 
patient groups not covered by this guideline 
are patients with CF bronchiectasis and chil-
dren up to and including 15 years of age.
Methodology
This guideline is based on the best avail-
able evidence. The methodology used to 
write the guideline adheres strictly to the 
criteria as set by the Appraisal of Guide-
lines, Research and Evaluation collabora-
tion, which is available online ( www. agreet-
rust. org/ resource- centre/ agree- ii/). The 
British Thoracic Society Standards of Care 
Committee guideline production manual 
is also available online (http://www. brit- 
thoracic. org. uk/ guidelines- and- quality- 
standards/).
clInIcAl questIons And lIterAture seArch
Clinical questions were structured in the 
PICO (Patient, Intervention, Control, 
Outcome) format (see full guideline, online 
appendix 11) to define the scope of the 
guideline and inform the literature search.
Systematic electronic database searches 
were conducted in order to identify poten-
tially relevant studies for inclusion in 
the guideline. For each topic area, the 
copyright.
 o
n
 4 February 2019 by guest. Protected by
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2018-000348 on 28 December 2018. Downloaded from 
2 Hill AT, et al. BMJ Open Resp Res 2018;5:e000348. doi:10.1136/bmjresp-2018-000348
Open access
Figure 1 Management of the deteriorating patient.
following databases were searched: Ovid MEDLINE 
(including MEDLINE In Process), Ovid EMBASE and 
the Cochrane Library (including the Cochrane Data-
base of Systematic Reviews, the Database of Abstracts 
of Reviews of Effects) from 1980.
The searches were first run in June 2014 and updated 
in June 2016 (see full guideline, appendix 2 for search 
strategy). Searches included a combination of indexed 
terms and free text terms and were limited to English 
language publications only. The initial search identified 
3848 potentialabstracts and the second search 1021 
abstracts.
consIdered judgeMent And grAdIng of evIdence
The Guideline Development Group used the evidence 
tables to judge the body of evidence and grade recom-
mendations for this guideline (see full guideline 
online appendix 3). An evidence level was assigned 
to each relevant study using Scottish intercollegiate 
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Figure 2 Stepwise management.
Antibiotics are used to treat exacerbations that present with an acute detrioration (usually over several days) with worsening local symptoms 
(cough,increased sputum volume or change of viscoisity, increased sputum purulence with or without increasing wheeze, breathlessness, 
haemoptypsis) and/ or systemic upset. The flow diagram refers to three or more annual exacerbations.
Figure 3 Physiotherapy management - stepwise airway clearance.
Guideline Network (SIGN) methodology (table 2), 
and where evidence was lacking to answer the formu-
lated clinical questions, expert opinions were obtained 
through consensus. The following were considered in 
grading of the recommendations:
•	 The available volume of the body of evidence.
•	 How applicable the obtained evidence was in making 
recommendations for the defined target audience of 
this guideline.
•	 Whether the evidence was generalisable to the target 
population for the guideline.
•	 Whether there was a clear consistency in the evidence 
obtained to support recommendations.
•	 What the implications of recommendations would be 
on clinical practice in terms of resources and skilled 
expertise.
•	 Cost-effectiveness was not reviewed in detail as 
in-depth economic analysis of recommendations falls 
beyond the scope of this guideline.
Recommendations were graded from A to D as 
indicated by the strength of the evidence as shown in 
table 3. In line with SIGN guidance, ‘minus’ evidence 
was considered in context, but in the absence of other 
‘plus’ supporting evidence, it was discussed among 
the Guideline Development Group (GDG) regarding 
that point and any recommendation hence made 
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Figure 4 Airway clearance - exacerbations.
Figure 5 Algorithm for initial assessment and treatement - rhinosinusitis.
was grade D. Important practical points lacking any 
research evidence nor likely to be research evidence 
in the future were highlighted as ‘Good Practice 
Points’.
drAftIng the guIdelIne
The GDG corresponded regularly by email and meet-
ings of the co-chairs subgroup and full group were held 
in January, May and June 2014; January, May, September 
and December 2015; January, April and December 
2016; January and November 2017. A number of 
teleconferences were also held. The BTS Standards 
of Care Committee (SOCC) reviewed the draft guide-
line in November 2017. The draft guideline was made 
available online March–April 2018 for public consul-
tation and circulated to all the relevant stakeholders. 
The BTS SOCC re-reviewed the revised draft guideline 
in June 2018 and final SOCC approval granted in July 
2018.
This BTS Guideline will be reviewed within 5 years 
from the publication date.
declArAtIons of Interest
All members of the Guideline Group made declara-
tions of interest in line with BTS Policy and further 
details can be obtained on request from BTS. Guide-
line Group members are listed in online appendix 1 to 
the full guideline.
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Table 1 Quick summary guide
Whom to investigate? Patients with persistent production of mucopurulent or purulent sputum particularly with relevant associated risk 
factors.
Patients with rheumatoid arthritis if they have symptoms of chronic productive cough or recurrent chest 
infections.
Patients with chronic obstructive pulmonary disease with frequent exacerbations (two or more annually) and a 
previous positive sputum culture for Pseudomonas aeruginosa while stable.
Patients with inflammatory bowel disease and chronic productive cough.
What radiology? Perform baseline chest X-ray.
Perform a thin-section CT.
What tests? Comorbidities and medical history should be recorded.
Investigations for reflux and aspiration in symptomatic patients, or where there are other suggestive clinical 
features.
Measure full blood count, serum total IgE and specific IgE or skin prick test to Aspergillus in all patients to 
investigate for allergic bronchopulmonary aspergillosis.
Measure serum IgG, IgA and IgM in all patients with bronchiectasis to exclude immunodeficiency.
Consider measuring baseline specific antibody levels against capsular polysaccharides of Streptococcus 
pneumoniae in all patients to investigate for specific antibody deficiency. If pneumococcal antibodies are low, 
immunise with 23 valentpolysaccharide pneumococcal vaccine, followed by measurement of specific antibody 
levels 4–8 weeks later.
Test for cystic fibrosis (according to NICE Guidelines for cystic fibrosis) in patients with supporting clinical 
features.
Test for PCD in patients with supporting clinical features. Measurement of nasal nitric oxide is the first-line 
investigation.
Send sputum cultures in all patients with bronchiectasis for routine and mycobacterial culture while clinically 
stable.
Airway clearance Management in stable disease—see figure 3
Management in exacerbations—see figure 4.
Stepwise management See (figure 2)
Antibiotic treatment for exacerbations—see table 6
Management of rhinosinusitis—see figure 5
Management of ABPA.
Offer oral corticosteroid to patients with active ABPA. An initial dose of 0.5 mg/kg/day, for 2 weeks is 
recommended.
Wean steroids according to clinical response and serum IgE levels.
Consider itraconazole as a steroid-sparing agent for patients dependent on oral corticosteroids where difficulty in 
weaning is experienced.
Monitor with total IgE level to assess treatment response.
The deteriorating patient A deteriorating patient is defined as significant and prolonged deterioration of symptoms, unexpected increased 
frequency or severity of exacerbations, frequent hospital admissions, early relapse after treatment of an 
exacerbation or rapid decline in lung function. A management plan to help in dealing with these patients is shown 
in figure 1.
Who should be followed 
up in secondary care
Patients with chronic P. aeruginosa, non-tuberculous mycobacteria or methicillin-resistant Staphylococcus aureus 
colonisation;
Deteriorating bronchiectasis with declining lung function;
Recurrent exacerbations (≥3 per year);
Patients receiving long-term antibiotic therapy (oral, inhaled or nebulised);
Patients with bronchiectasis and associated rheumatoid arthritis, immune deficiency, inflammatory bowel disease 
and primary ciliary dyskinesia;
Patients with allergic bronchopulmonary aspergillosis;
Patients with advanced disease and those considering transplantation.
Monitoring See tables 4 and 5 for severity assessment.
See table 7 for monitoring.
ABPA, Allergic broncho pulmonary aspergillosis; NICE, National Institute for Health and Care Excellence: NTM, Non tuberculous mycobacteria; PCD, 
Primary Ciliary Dyskinesia.
representAtIon And stAkeholder orgAnIsAtIons
Professor Michael Loebinger represented the Royal 
College of Physicians, London. Dr Kevin Gruffydd-Jones 
represented the Primary Care Respiratory Society UK. 
Ms Karen Payne represented the Association of Respira-
tory Nurse Specialists. Ms Lizzie Grillo represented the 
Association of Chartered Physiotherapists in Respiratory 
Care.
suMMAry of recoMMendAtIons And good prActIce 
poInts
how should the diagnosis of bronchiectasis be determined?
Recommendations – Imaging
 ► Perform baseline chest X-ray in patients with 
suspected bronchiectasis (D).
 ► Perform a thin-section CT to confirm a diagnosis of 
bronchiectasis when clinically suspected (C).
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Table 2 Levels of evidence
Grade Evidence
1++ High-quality meta-analyses, systematic reviews of 
RCTs or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews 
of RCTs or RCTs with a low risk of bias
1− Meta-analyses, systematic reviews of RCTs or 
RCTs with a high risk of bias
2++ High-quality systematic reviews of case–control 
or cohort studies or high-quality case–control or 
cohort studies with a very low risk of confounding, 
bias or chance and a high probability that the 
relationship is casual
2+ Well-conducted case–control or cohort studies with 
a low risk of confounding, bias or chance and a 
moderate probability that the relationship is casual
2− Case–control or cohort studies with a high risk of 
confounding, bias or chance and a significant risk 
that the relationship is not casual
3 Non-analytic studies, for example, case reports, 
case series
4 Expert opinion
RCT, randomised control trial.
Table 3 Grades of recommendation body of evidence 
including studies r
Grade Type of evidence
A At least one meta-analysis, systematic review or 
RCT rated as 1++ and directly applicable to the 
target population orA systematic review of RCTs 
or a body of evidence consisting principally of 
studies rated as 1+ directly applicable to the target 
population and demonstrating overall consistency 
of results
B A body of evidence including studies rated as 
2++ directly applicable to the target population 
and demonstrating overall consistency of results 
orExtrapolated evidence from studies rated as 1++ 
or 1+
C A body of evidence including studies rated as 2+ 
directly applicable to the target population and 
demonstrating overall consistency of results or 
Extrapolated evidence from studies rated  
as 2++
D Evidence of level 3 or 4 orExtrapolated evidence 
from studies rated as 2+
√ Important practical points for which there is no 
research evidence, nor is there likely to be any 
research evidence. The guideline committee 
wishes to emphasise these Good  
Practice Points
RCT, randomised controlled trial.
 ► Perform baseline imaging during clinically stable 
disease as this is optimal for diagnostic and serial 
comparison purposes (D).
Good practice points
CT imaging protocol
 ✔ The most appropriate imaging protocol will vary ac-
cording to scanner technology and patient factors.
 ✔ When using volumetric CT, dose-reduction tech-
niques including adaptive milliampere and kilovolt 
and iterative reconstruction should be used where 
available.
 ✔ Typical CT imaging parameters for the diagnosis of 
bronchiectasis are:
 ✔ Slice thickness: ≤1 mm.
 ✔ Reconstruction algorithm: high spatial frequency.
 ✔ kVp: 100–140.
 ✔ mAs (or effective mAs): 100–200.
 ✔ Gantry rotation time: <0.5 s.
CT features of bronchiectasis
 ✔ Bronchiectasis is defined by bronchial dilatation as 
suggested by one or more of the following:
 – Bronchoarterial ratio >1 (internal airway lumen vs 
adjacent pulmonary artery).
 – Lack of tapering.
 – Airway visibility within 1 cm of costal pleural sur-
face or touching mediastinal pleura.
 ✔ The following indirect signs are commonly associated 
with bronchiectasis:
 – Bronchial wall thickening.
 – Mucus impaction.
 – Mosaic perfusion/air trapping on expiratory CT.
General
 ✔ CT scanning can also aid in identifying an aetiology 
of bronchiectasis, for example Allergic broncho pul-
monary aspergillosis (ABPA), Non tuberculous myco-
bacteria (NTM), primary ciliary dyskinesia, alpha one 
antitrypsin deficiency, Williams-Campbell syndrome 
and a foreign body.
In whom should the diagnosis of bronchiectasis be 
suspected?
Recommendations
 ► Consider investigation for bronchiectasis in patients 
with persistent production of mucopurulent or puru-
lent sputum particularly with relevant associated risk 
factors (D).
 ► Consider investigation for bronchiectasis in patients 
with rheumatoid arthritis if they have symptoms of 
chronic productive cough or recurrent chest infec-
tions (C).
 ► Consider investigation for bronchiectasis in patients 
with chronic obstructive pulmonary disease (COPD) 
with frequent exacerbations (two or more annually) 
and a previous positive sputum culture for Pseu-
domonas aeruginosa while stable (B).
 ► Consider investigation for bronchiectasis in patients 
with inflammatory bowel disease and chronic produc-
tive cough (C).
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Table 4 Variables involved in calculating the severity score in the Bronchiectasis Severity Index
Factorand points for scoring system 
Age (years) <50 (0 points) 50–69 (2 points) 70–79 (4 points) >80 (6 points)
Body Mass Index (kg/m2) <18.5 (2 points) 18.5–25 (0 points) 26–30 (0 points) >30 (0 points)
FEV1 % predicted >80 (0 points) 50–80 (1 point) 30–49 (2 points) <30 (3 points)
Hospital admission within last 2 years No (0 points) Yes (5 points) 
No of exacerbations in previous 12 months 0 (0 points) 1–2 (0 points) ≥3 (2 points) 
MRC breathlessness score 1–3 (0 points) 4 (2 points) 5 (3 points) 
P. aeruginosa colonisation No (0 points) Yes (3 points) 
Colonisation with other organisms No (0 points) Yes (1 point) 
Radiological severity <3 lobes affected 
(0 points)
≥3 lobes or cystic bronchiectasis in any lobe (1 point) 
0-4 Points=mild disease; 5–8=moderate disease; 9 and over=severe disease.
MRC, Medical Research Council.
Table 5 Variables involved in calculating severity in the FACED score
Factor and points for scoring system
FEV1 % predicted <50 (2 points) ≥50 (0 points)
Age (years) <70 (0 points) >70 (2 points)
Colonisation by P. aeruginosa No (0 points) Yes (1 point)
Radiological extension of bronchiectasis 1–2 lobes (0 points) >2 lobes (1 point)
Modified MRC Dyspnoea Scale 1–2 (0 points) III–IV (1 point)
0–2 Points=mild disease; 3–4=moderate disease; 5–7=severe disease.
FACED, score FEV1, Age, Chronic colonisation, Extension, Dyspnoea: MRC, Medical Research Council.
Good practice points
 ✔ In at-risk groups, if bronchiectasis is suspected, bron-
chiectasis needs confirmation.
 ✔ In patients with COPD, investigation for bronchiec-
tasis may be appropriate especially in the presence 
of chronic productive cough with positive sputum 
cultures for potential pathogenic micro-organism 
(PPM) while stable or two or more exacerbations in 
the preceding 12 months.
 ✔ In patients with asthma, investigation for bronchiec-
tasis may be appropriate with severe or poorly con-
trolled disease.
 ✔ In patients with a history of HIV-1 infection, solid 
organ and bone marrow transplant, and history of 
immunosuppressive therapy for lymphoma and vas-
culitis, investigation for bronchiectasis may be appro-
priate with symptoms of chronic productive cough or 
recurrent chest infections.
 ✔ In patients with chronic rhinosinusitis, investigation 
for bronchiectasis may be appropriate with symptoms 
of chronic productive cough or recurrent chest infec-
tions.
 ✔ In patients with other connective tissue disease or 
inflammatory bowel disease, investigation for bron-
chiectasis may be appropriate if they have symptoms 
such as chronic productive cough or recurrent chest 
infections.
 ✔ Investigation for bronchiectasis may be appropriate 
in otherwise healthy individuals with a cough that 
persists for longer than 8 weeks, especially with spu-
tum production or a history of an appropriate trigger 
(see BTS Recommendations for the management of 
cough in adults 4).
Investigations for causes of bronchiectasis
Recommendations
 ► A panel of investigations should be performed to 
establish the underlying cause of bronchiectasis (B). 
(table 1)
a. Comorbidities and medical history should be 
recorded in patients diagnosed with bronchiectasis 
to identify relevant and possibly causative disease 
such as rheumatoid arthritis, COPD, asthma, 
gastro-oesophageal reflux disease and inflamma-
tory bowel disease (C).
b. Measure full blood count, serum total IgE and 
assessment of sensitisation (specific IgE or skin 
prick test) to Aspergillus fumigatus in all patients 
with bronchiectasis (D).
c. Serum IgG, IgA and IgM should be performed in 
all patients with bronchiectasis (C).
d. Consider measuring baseline specific anti-
body levels against capsular polysaccharides of 
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Table 6 Common organisms associated with acute exacerbation of bronchiectasis and suggested antimicrobial agents—
adults
Organism Recommended first-line treatment
Length of 
treatment 
(days) Recommended second-line treatment
Length of 
treatment 
(days)
Streptococcus
pneumoniae
Amoxicillin
500 mg three times a day
14 Doxycycline 100 mg twice a day 14
Haemophilus influenzae—beta 
lactamase negative
Amoxicillin
500 mg three times a day
or
Amoxicillin
1 g three times a day
or
Amoxicillin
3 g twice a day
14 Doxycycline 100 mg twice a day
or
Ciprofloxacin
500 mg or 750 mg twice a day
or
Ceftriaxone 2 g once a day (intravenous)
14
Haemophilus influenzae—beta 
lactamase positive
Amoxicillin with clavulanic
acid 625 mg 1 tablet three times a day
14 Doxycycline
100 mg twice a day
or
Ciprofloxacin
500 mg or 750 mg twice a day
or
Ceftriaxone 2 g once a day (intravenous)
14
Moraxella catarrhalis Amoxicillin with clavulanic
acid 625 mg 1 tablet three times a day
14 Clarithromycin 500 mg twice a day
or
Doxycycline 100 mg twice a day
or
Ciprofloxacin
500 mg
or 750 mg twice a day
14
Staphylococcus aureus (MSSA) Flucloxacillin 500 mg four times a day 14 Clarithromycin 500 mg twice a day
or
Doxycycline 100 mg twice a day
or
Amoxicillin with clavulanic acid 625 mg 1 tablet three 
times a day
14
Staphylococcus aureus (MRSA) 
oral preparations
Doxycycline 100 mg twice a day
Rifampicin (<50 kg) 450 mg 
once a day 
Rifampicin (>50 kg) 600 mg once a day 
Trimethoprim 200 mg twice a day
14 Third-line linezolid 600 mg twice a day 14 
 
 
Staphylococcus aureus (MRSA) 
intravenous preparations
Vancomycin 1 g twice a day* (monitor 
serum levels and adjust dose 
accordingly) or teicoplanin 400 mg once 
a day
14 Linezolid 600 mg twice a day 14
Coliforms, eg, Klebsiella, 
Enterobacter
Oral ciprofloxacin 500 mg or 750 mg 
twice a day
14 Intravenous ceftriaxone 2 g once a day 14
Pseudomonas aeruginosa Oral ciprofloxacin 500 mg twice a 
day(750 mg twice a day in more severe 
infections)
14 
 
Monotherapy:
intravenous ceftazidime 2 g three times a day
or
piperacillin with tazobactam 4.5 g three times a day
or
aztreonam 2 g three times a day
or
meropenem 2 g three times a day
 
Combination therapy:
the above can be combined with gentamicin or 
tobramycin or
colistin 2 mU three times a day (under 60 kg, 50 000–
75 000 U/kg daily in 3 divided doses)
 
Patients can have an in vivo response despite in 
vitro resistance. Caution with aminoglycosides as 
highlighted below but also if previous adverse events, 
particularly previous ototoxicity/acute kidney injury due 
to aminoglycosides
14
Caution with aminoglycosides in pregnancy, renal failure, elderly or on multiple other drugs.
*Elderly (over 65 years), 500 mg Vancomycin every 12 hours or 1 g once daily BNF 72 (March 2017).
IV, intravenous; MRSA, methicillin-resistant S.aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
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Table 7 Routine monitoring tests
Mild disease severity Moderate–severe
Severity Index scoring Baseline Baseline
Body Mass Index Annual Annual
Exacerbation history Annual 6 monthly
Sputum culture Annual 6 monthly
MRC Dyspnoea Score Annual 6 monthly
Spirometry Annual Annual
CT (radiological extent) At diagnosis*‡ At diagnosis*‡
Sputum mycobacterial culture† Baseline‡ Baseline‡
Oxygen saturation monitoring (SpO2) Annual 6 monthly
Aetiological investigations At diagnosis‡ At diagnosis‡
Comorbidities assessment At diagnosis‡ At diagnosis‡
*Consider repeat CT scanning in patients with primary immunodeficiency with scan interval of 3-5-years.
†This may need tailored in light of the local prevalence rates of NTM infections and in some centres may need undertaken on a regular basis. 
Further cultures at exacerbationmay be appropriate.
‡Repeat investigations if a deteriorating patient.
MRC, Medical Research Council.
Streptococcus pneumoniae in all patients to investigate 
for specific antibody deficiency. If pneumococcal 
antibodies are low, immunise with 23 valent poly-
saccharide pneumococcal vaccine, followed by 
measurement of specific antibody levels 4–8 weeks 
later (D).
e. Test for cystic fibrosis (according to the National 
Institute for Health and Care Excellence (NICE) 
Guidelines for CF) in patients with supporting 
clinical features, for example early onset, male 
infertility, malabsorption and pancreatitis (B).
f. Test for Primary Ciliary Dyskinesia (PCD) 
(according to ERS Guidelines for PCD Diagnosis) 
in patients with supporting clinical features, 
including a history of neonatal distress, symptoms 
from childhood, recurrent otitis media, rhinosi-
nusitis or infertility (A).
g. Sputum cultures should be performed in all 
patients with bronchiectasis for routine and myco-
bacterial culture (D).
Good practice points
 ✔ A previous diagnosis of idiopathic bronchiectasis 
should prompt careful reinvestigation for a primary 
cause in the context of a deteriorating clinical course 
or a young patient (us ually considered to be age 50 
and under but not limited to this age group).
 ✔ Referral to a specialist centre for investigation should 
be considered for young patients (usually considered 
to be age 50 and under but not limited to this age 
group) and those with apparent idiopathic bronchi-
ectasis especially where there is evidence of progres-
sive disease.
 ✔ Consider testing for rheumatoid factor (RF), anti-cy-
clic citrullinated peptide (CCP), anti-nuclear antibod-
ies (ANA) and anti-neutrophil cytoplasmic antibodies 
(ANCA) in patients with coexisting clinical features 
of arthritis, connective tissue disease and/or systemic 
vasculitis.
 ✔ Consider testing for A1AT deficiency in patients with 
coexisting basal panacinar emphysema.
 ✔ Investigations for reflux and aspiration should be un-
dertaken only in symptomatic patients or where there 
are other suggestive clinical features.
 ✔ Consider bronchoscopy for patients with localised 
disease to rule out an endobronchial lesion or foreign 
body as the cause of bronchiectasis.
 ✔ A bronchial aspiration or bronchial wash targeting 
the areas of bronchiectasis from CT scan of the chest 
should be considered in patients who do not expecto-
rate and can be particularly helpful in the diagnosis 
of NTM pulmonary disease.
 ✔ Serum protein electrophoresis should be performed 
in all patients with bronchiectasis with raised immu-
noglobulins.
 ✔ Consider HIV-1 serology in patients with bronchiec-
tasis depending on prevalence of HIV-1 and clinical 
features suggestive of increased risk of retroviral in-
fection.
Research recommendations
Consensus criteria for diagnosis of ABPA need to be 
validated in bronchiectasis cohorts.
Consensus criteria for definition of abnormal 
post-pneumococcal test immunisation antibody 
responses need to be validated in bronchiectasis 
cohorts.
severity scoring
Good practice point
 ✔ Consider using the Bronchiectasis Severity Index, 
which may help guide management (tables 4 and 
5).
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stable state treatment
Which patients should be taught airway clearance 
techniques?
Recommendation
 ► Teach individuals with bronchiectasis to perform 
airway clearance (D).
Good practice points
 ✔ Airway clearance techniques should be taught by a 
respiratory physiotherapist.
 ✔ At initial assessment, a respiratory physiotherapist 
should educate the patient about their condition and 
if appropriate give advice on adjuncts (inhaled/oral 
therapy or exercise) that may enhance effectiveness 
of their chosen airway clearance technique.
 ✔ Patients admitted with an exacerbation of bronchiec-
tasis should be seen daily by a respiratory physiother-
apist until their airway clearance is optimised.
Which airway clearance techniques should be taught?
Recommendations
 ► Offer active cycle of breathing technique or oscil-
lating positive expiratory pressure to individuals with 
bronchiectasis (D).
 ► Consider gravity-assisted positioning (where not 
contraindicated) to enhance the effectiveness of an 
airway clearance technique (D).
Good practice points
 ✔ CT imaging should be reviewed to complement the 
physiotherapy assessment. Where indicated, this in-
formation could be used in order to teach the patient 
the appropriate postural drainage position(s) for 
their affected bronchopulmonary segment(s).
 ✔ Patients should be made aware of the range of availa-
ble airway clearance techniques.
 ✔ Consider patient preference and adherence when 
recommending an airway clearance technique.
 ✔ Consider the inclusion of the forced expiration tech-
nique (huff) for all airway clearance techniques.
 ✔ Consider modified postural drainage (no head down 
tilt) in patients for whom postural drainage is con-
traindicated or not tolerated.
 ✔ If symptoms of gastro-oesophageal reflux increase 
with modified postural drainage (no head down tilt), 
an airway clearance technique in the sitting position 
should be taught.
 ✔ Consider autogenic drainage, positive expiratory 
pressure, high-frequency chest wall oscillation and in-
trapulmonary percussive ventilation as an alternative 
airway clearance technique if other techniques are 
not effective or acceptable to the patient.
 ✔ Patients should be encouraged to perform regular 
physical exercise (plus the forced expiration tech-
nique/huff) to promote airway clearance.
 ✔ If there is ongoing haemoptysis, refer back to the res-
piratory physiotherapist to determine the optimum 
airway clearance technique.
Airway clearance technique during an acute exacerbation
Good practice points
 ✔ Manual techniques may be offered to enhance spu-
tum clearance when the patient is fatigued or under-
going an exacerbation.
 ✔ Consider intermittent positive pressure breathing or 
non-invasive ventilation during an acute exacerbation 
to offload the work of breathing so fatigued and/or 
breathless patients can tolerate a longer treatment 
session and can adopt postural drainage positions.
Research recommendations
Randomised controlled trials using clinically 
important outcome measures are required to assess the 
effectiveness of airway clearance techniques in varying 
severities of bronchiectasis.
Randomised controlled trials are required to evaluate 
the effects of airway clearance techniques in patients 
who are undergoing an exacerbation.
how often should patients carry out airway clearance 
techniques? how long should an airway clearance session 
last?
Good practice points
 ✔ The frequency and duration of the airway clearance 
technique should be tailored to the individual and 
may alter during periods of exacerbation.
 ✔ Advise individuals to perform their airway clearance 
technique for a minimum of 10 min (up to a maxi-
mum of 30 minutes). After this time, they should con-
tinue until two clear huffs or coughs are completed, 
or until the patient is starting to become fatigued.
how soon should the patient be reviewed after the initial 
assessment?
Good practice points
 ✔ Individuals whot have been assessed and taught an 
airway clearance technique should be reviewed by a 
respiratory physiotherapist within 3 months of their 
initial assessment.
 ✔ Individuals with bronchiectasis who are followed up 
in secondary care should be assessed by a respiratory 
physiotherapist as part of their annual clinical review 
to ensure their airway clearance regimen is optimised.
 ✔ All individuals with a deterioration in their condition 
(increased frequency of exacerbations and/or wors-
ening of symptoms) should have their airway clear-
ance technique reviewed by a respiratory physiother-
apist (see figure 1–management of the deteriorating 
patient).
Mucoactives in bronchiectasis
Recommendations
 ► Do not routinely use recombinant human DNase in 
adults with bronchiectasis (A).
 ► Consider the use of humidification with sterile water 
or normal saline to facilitate airway clearance (D).
copyright.
 o
n
 4 February 2019 by guest. Protected by
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2018-000348 on 28 December 2018. Downloaded from 
Hill AT, et al. BMJ Open Resp Res 2018;5:e000348. doi:10.1136/bmjresp-2018-000348 11
Open access
Good practice points
 ✔ Consider a trial of mucoactive treatment in patients 
with bronchiectasis who have difficulty in sputum ex-
pectoration.
 ✔ Perform an airway reactivity challenge test when in-
haled mucoactive treatment is first administered.
 ✔ Consider pretreatment with a bronchodilator prior to 
inhaled or nebulised mucoactive treatments especial-
ly in individuals where bronchoconstriction is likely 
(patients with asthma or bronchial hyper-reactivity 
and those with severe airflow obstruction FEV1 <1 li-
tre).
 ✔ If carbocysteine is prescribed, a 6-month trial should 
be given and continued if there is ongoing clinical 
benefit.
 ✔ See figures 3 and 4.
 ✔ See Full Guideline appendix 2: Challenge test details.
Research recommendation
Randomised controlled trials are needed to assess the 
long-term impact of mucoactive therapies.
What is the evidence for long-term anti-inflammatory 
therapies in bronchiectasis?
Recommendations
 ► Do not routinely offer inhaled corticosteroids to 
patients with bronchiectasis without other indications 
(such as ABPA, chronic asthma, COPD and inflamma-
tory bowel disease) (B).
 ► Do not offer long-term oral corticosteroids for 
patients with bronchiectasis without other indications 
(such as ABPA, chronic asthma, COPD, inflammatory 
bowel disease) (D).
 ► Do not routinely offer PDE4 inhibitors, methylxan-
thines or leukotriene receptor antagonists for bron-
chiectasis treatment (D).
 ► Do not routinely offer CXCR2 antagonists, neutro-
phil elastase inhibitors or statins for bronchiectasis 
treatment (B).
Good practice point
 ✔ Inhaled corticosteroids have an established role in 
the management of asthma and a proportion of pa-
tients with COPD, which are common comorbid con-
ditions in bronchiectasis.
Research recommendation
Randomised controlled trials are needed to assess the 
long-term impact of anti-inflammatory therapies.
What treatments improve outcomes for patients with stable 
bronchiectasis?
Recommendations
 ► Consider long -term antibiotics in patients with bron-
chiectasis who experience three or more exacerba-
tions per year (A). (see figure 2 and full guideline 
appendix 2 and 3)
 ► In these patients, the following are recommended
P. aeruginosa colonised patients
a. Use inhaled colistin for patients with bronchiectasis 
and chronic P. aeruginosa infection. (B)
b. Consider inhaled gentamicin as a second line alter-
native to colistin for patients with bronchiectasis and 
chronic P. aeruginosa infection. (B)
c. Consider azithromycin or erythromycin as an alter-
native (eg if a patient does not tolerate inhaled an-
tibiotics) to an inhaled antibiotic for patients with 
bronchiectasis and chronic P. aeruginosa infection. 
(B)
d. Consider azithromycin or erythromycin as an additive 
treatment to an inhaled antibiotic for patients with 
bronchiectasis and chronic P. aeruginosa infection 
who have a high exacerbation frequency. (D)
Non- P. aeruginosa colonised patients
e. Use azithromycin or erythromycin for patients with 
bronchiectasis. (A)
f. Consider inhaled gentamicin as a second line alterna-
tive to azithromycin or erythromycin (B)
g. Consider doxycycline as an alternative in patients intol-
erant of macrolides or in whom they are ineffective. (C) 
Good practice points
 ✔ Antimicrobial stewardship is important.
 ✔ Prior to starting long-term macrolides, for safety rea-
sons, (1) ensure no active NTM infection with at least 
one negative respiratory NTM culture; (2) use with 
caution if patient has significant hearing loss needing 
hearing aid(s) or significant balance issues.
 ✔ Prior to starting long-term inhaled aminoglycosides, 
for safety reasons, (1) avoid using if creatinine clear-
ance <30 mL/min, (2) use with caution if patient has 
significant hearing loss needing hearing aid(s) or 
significant balance issues; (3) avoid concomitant ne-
phrotoxic medications.
 ✔ Counsel patients about potential major side effects 
with long-term antibiotics and to seek urgent atten-
tion if these develop.
a. Review the patient’s culture and mycobacterial 
status, optimise airway clearance and treat other 
associated conditions before starting long-term 
antibiotics.
b. Prophylactic antibiotics should be only started by 
respiratory specialists.
c. Review patients on long-term antibiotics 6 monthly 
with assessment of efficacy, toxicity and continuing 
need. Monitor sputum culture and sensitivity regu-
larly, although in vitro resistance may not affect 
clinical efficacy.
 ✔ As adverse event frequency of azithromycin is likely to 
be dose related, 250 mg 3 times a week is a pragmatic 
starting dose which can then be increased according 
to clinical response and adverse events.
 ✔ Thresholds for long-term treatment may reduce if the 
patient is symptomatic between exacerbations and/or 
the exacerbations respond poorly to treatment and/
or the patient is at high risk of severe exacerbation, 
for example, immunosuppressed.
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 ✔ Long-term antibiotic choice is complex and has to 
take into account factors such as tolerance, allergies 
and sensitivity; therefore, in some circumstances, oth-
er long-term antibiotic regimens may be appropriate 
(see full guideline appendix 3).
 ✔ Perform a suitable challenge test when stable before 
starting inhaled antibiotics (see full guideline appen-
dix 2).
 ✔ Consider cyclical intravenous antibiotics in patients 
with repeated infections (≥5/year) despite other 
treatments.
 ✔ Alternative inhaled/nebulised agents may become li-
censed as international studies are completed.
 ✔ For patients receiving long-term prophylactic oral 
antibiotics, the preferred option is to remain on the 
same antibiotic as opposed to monthly rotation of an-
tibiotics. If there is a subsequent lack of efficacy, the 
antibiotic can be changed guided by sensitivity results.
Research recommendations
Long-term randomised controlled trials of oral and 
inhaled antibiotics are needed to assess their efficacy 
and safety in patients with bronchiectasis who have 
frequent respiratory tract infections with recurrent 
P. aeruginosa infection or other potential pathogenic 
micro-organisms.
does long-term bronchodilator treatment improve outcomes 
for patients with bronchiectasis?
Recommendations
 ► Use of bronchodilators in patients with bronchiec-
tasis and coexisting COPD or asthma should follow 
the guideline recommendations for COPD or asthma 
(D).
 ► Offer a trial of long-acting bronchodilator therapy in 
patients with symptoms of significant breathlessness 
(D).
 ► Reversibility testing to beta-2 agonist or anticholin-
ergic bronchodilators may help to identify patients 
with coexisting asthma, but there is no evidence to 
suggest that a response is required in order to benefit 
from bronchodilators (D).
pulmonary rehabilitation
Recommendations
 ► Offer pulmonary rehabilitation to individuals who are 
functionally limited by shortness of breath (Modified 
Medical Research Council Dyspnoea Scale ≥1) (B).
 ► Consider the use of inspiratory muscle training in 
conjunction with conventional pulmonary rehabil-
itation to enhance the maintenance of the training 
effect (B).
Good practice points
 ✔ Educate all individuals with bronchiectasis on the im-
portance of an exercise training programme.
 ✔ Consider the 6 minute walk test (6MWT) and/or the 
incremental shuttle walking test (ISWT) when evalu-
ating exercise capacity before/after pulmonary reha-
bilitation in bronchiectasis. Prior to this, practice tests 
should be carried out to eliminate any learning effect.
 ✔ Pulmonary rehabilitation providers should offer ed-
ucation sessions tailored to the needs of individuals 
with bronchiectasis (eg, airway clearance techniques, 
the pathophysiology of bronchiectasis and relevant 
inhaled therapy).
 ✔ Pulmonary rehabilitation exercise and education ses-
sions should be provided by appropriately qualified 
healthcare practitioners.
Further information on pulmonary rehabil-
itation is provided in the BTS Quality Stand-
ards for Pulmonary rehabilitation (https://www. 
brit- thoracic. org. uk/ standards- of- care/ quality- standards/ 
bts- pulmonary- rehabilitation- quality- standards/).
Research recommendation
The role of education, self-management plans and 
who delivers the pulmonary rehabilitation needs to be 
explored.
The role of pulmonary rehabilitation after exacerba-
tions requiring hospital admission needs to be explored.
The incidence of cross-infection of respiratory patho-
gens in the group exercise setting should be investigated 
in the bronchiectasis population.
What is the role of surgery in managing bronchiectasis?
Recommendations
 ► Consider lung resection in patients with local-
ised disease whose symptoms are not controlled by 
medical treatment optimised by a bronchiectasis 
specialist (D).
 ► Offer multidisciplinary assessment, including a bron-
chiectasis physician, a thoracic surgeon and an expe-
rienced anaesthetist, of suitability for surgery and 
preoperative assessment of cardiopulmonary reserve 
post resection (D).
Good practice point
 ✔ Consider nutritional support and preoperative pul-
monary rehabilitation before surgical referral.
lung transplantation for bronchiectasis
Recommendations
 ► Consider transplant referral in bronchiectasis patients 
aged 65 years or less if the FEV1 is <30% with signifi-
cant clinical instability or if there is a rapid progres-
sive respiratory deterioration despite optimal medical 
management (D).
 ► Consider earlier transplant referral in patients 
with bronchiectasis with poor lung function and 
the following additional factors: massive haemop-
tysis, severe secondary pulmonary hypertension, 
intensive care unit admissions or respiratory failure 
(particularly if requiring non invasive ventilation 
(NIV)) (D).
Good practice points
 ✔ Discuss appropriate patients with a transplant centre 
prior to formal referral.
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 ✔ Optimise management of comorbidities such as oste-
oporosis and maintaining physical condition through 
pulmonary rehabilitation prior to transplant.
What is the role of influenza and pneumococcal vaccination 
in management of bronchiectasis?
Recommendations
 ✔ Offer annual influenza immunisation to all patients 
with bronchiectasis (D).
 ✔ Offer polysaccharide pneumococcal vaccination to all 
patients with bronchiectasis (D).
Good practice point
 ✔ Consider influenza vaccination in household contacts 
of patients with immune deficiency and bronchiecta-
sis to reduce the risks of secondary transmission.
 ✔ Consider use of 13 valent protein conjugate pneu-
mococcal vaccine in patients with bronchiectasis who 
do not have an appropriate serological response to 
standard polysaccharide vaccine (23 valent carbohy-
drate pneumococcal vaccine).
treatment of respiratory failure
Recommendations
 ► Consider long-term oxygen therapy for patients with 
bronchiectasis and respiratory failure, using the same 
eligibility criteria as for COPD (D).
 ► Consider domiciliary non-invasive ventilation for 
patients with bronchiectasis and respiratory failure 
associated with hypercapnia, especially where this is 
associated with symptoms or recurrent hospitalisation 
(D).
bronchiectasis and other treatments
Recommendation
 ► Do not routinely recommend alternative treatments 
(for example cough suppression, nutritional supple-
mentation, complementary therapy/homeopathy, 
supplemental treatments) as part of the management 
of patients with bronchiectasis (D).
Good practice point
 ✔ Record patient’s weight and Body Mass Index at each 
clinic appointment.
Research recommendations
Further interventional/randomised controlled trials 
are needed to establish the role of any alternative thera-
pies in the management of bronchiectasis.
Studies assessing the benefits of nutritional supple-
mentation in patients with bronchiectasis should be 
undertaken.
do pathogens have an impact on prognosis in 
bronchiectasis?
Recommendations
 ► Consider patients with chronic P. aeruginosa colonisa-
tion at higher risk of bronchiectasis-related complica-
tions (B).
 ► Perform regular sputum microbiology screening for 
patients with clinically significant bronchiectasis to 
monitor for pathogens and detect new isolation of P. 
aeruginosa (C).
What is the evidence of for the role of viruses/fungal diseases 
in patients with bronchiectasis?
Good practice points
 ✔ Testing to detect viral infection should be considered 
in patients with an exacerbation of bronchiectasis.
 ✔ Do not routinely use antifungal therapy without 
evidence of fungal disease. Fungal cultures can 
be positive in those receiving long-term antibiotic 
therapy.
does eradication of potentially pathogenic micro-organisms 
improve outcomes in patients with stable bronchiectasis?
Recommendations
 ► Offer patients with bronchiectasis associated with clin-
ical deterioration and a new growth of P. aeruginosa 
(first isolation or regrowth in the context of intermit-
tently positive cultures) eradication antibiotic treat-
ment (first-line treatment: ciprofloxacin 500–750 
mg twice per day for 2 weeks; second-line treatment: 
intravenous anti-pseudomonal beta-lactam ± an intra-
venous aminoglycoside for 2 weeks, followed by a 
3-month course of nebulised colistin, gentamicin or 
tobramycin) (D).
 ► Discuss with patients the potential risks and benefits 
of starting eradication antibiotic treatment versus 
clinical observation following a new growth of P. aerug-
inosa in the context of stable bronchiectasis. This will 
include consideration of the likelihood of achieving 
sustained eradication, the risk of developing chronic 
infection and the risk of adverse events with each 
management approach (D).
 ► Offer patients with bronchiectasis associated with 
clinical deterioration and a new growth of methicil-
lin-resistant Staphylococcus aureus (first isolation or 
regrowth in the context of intermittently positive 
cultures) eradication. This should be attempted espe-
cially in view of infection control issues (D).
Good practice point
 ✔ Send sputum for culture and sensitivity immediately 
before and at each clinical attendance following anti-
biotics prescribed for bacterial eradication to deter-
mine the outcome of treatment.
Research recommendation
A randomised control trial of P. aeruginosa eradication 
therapy is needed to determine the microbiological and 
clinical outcomes of eradication therapy.
does antibiotic therapy improve outcomes in patients with an 
exacerbation of bronchiectasis?
Good practice points
 ✔ A patient self-management plan should be consid-
ered; an example is provided online (https://www. 
brit- thoracic. org. uk/ standards- of- care/ quality- stand-
ards/ bts- bronchiectasis- quality- standards/) (see ta-
ble 6).
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 ✔ There should be prompt treatment of exacerbations 
and suitable patients should have antibiotics to keep 
at home.
 ✔ Previous sputum bacteriology results can be useful in 
deciding which antibiotic to use. Table 6 highlights 
the ﬁrst-line and alternative treatments for the com-
mon bacterial pathogens implicated in exacerbations 
of bronchiectasis.
 ✔ Where possible, sputum (spontaneous or induced) 
should be obtained for culture and sensitivity testing 
prior to commencing antibiotics.
 ✔ Empirical antibiotics can then be started while await-
ing sputum microbiology.
 ✔ Once a pathogen is isolated, antibiotics can be mod-
ified if there is no clinical improvement, with treat-
ment guided by antibiotic sensitivity results.
 ✔ In general, antibiotic courses for 14 days are standard 
and should always be used in patients infected with 
P. aeruginosa. Shorter courses may suffice in patients 
with mild bronchiectasis.
 ✔ Intravenous antibiotics should be considered when 
patients are particularly unwell, have resistant organ-
isms or have failed to respond to oral therapy (this is 
most likely to apply to patients with P. aeruginosa).
What treatments improve outcomes in patients with 
bronchiectasis and allergic bronchopulmonary aspergillosis?
Recommendations
 ► Offer oral corticosteroid to patients with active ABPA. 
An initial dose of 0.5 mg/kg/day for 2 weeks is recom-
mended. Wean steroids according to clinical response 
and serum IgE levels (D)
 ► Consider itraconazole as a steroid-sparing agent for 
patients dependent on oral corticosteroids where 
difficulty in weaning is experienced (B)
 ► Monitor patients with active ABPA with total IgE level 
to assess treatment response (C)
does immunoglobulin replacement treatment therapy 
improve outcomes in patients with bronchiectasis due to 
antibody deficiency?
Recommendations
 ► Offer IgG therapy to all patients with common vari-
able immune deficiency (CVID) and x linked agam-
maglobulnemia (XLA) (B)
 ► Consider IgG therapy for patients with specific poly-
saccharide antibody deficiency and/or IgA deficiency 
or IgG subclass deficiencies with absent/impaired 
pneumococcal vaccine antibody responses who 
continue to have objective evidence of bacterial sino-
pulmonary infection and progressive disease despite 
appropriate management of bronchiectasis (C).
Good practice point
 ✔ All patients receiving IgG replacement therapy should 
be under the joint care of a clinical immunologist and 
respiratory specialist in bronchiectasis
 ✔ Offer patients receiving replacement IgG the choice 
of hospital or home-based therapy.
Research recommendation
Randomised controlled trials are needed to assess 
which patients with bronchiectasis would benefit from 
long-term immunoglobulin G replacement therapy 
alone or as an adjunct to long-term antibiotic therapy—
assessing the optimal dose of IgG replacement and 
identification of ideal trough IgG level to prevent 
recurrent infections.
gastro-oesophageal reflux disease (gord) and bronchiectasis
Recommendation
 ► Treat GORD symptoms in patients with bronchiec-
tasis according to existing NICE guidance5 (D)
Good practice Points
 ✔ GORD should be considered in patients with hiatus 
hernia, persistent coliforms in sputum samples or re-
current exacerbations with no other cause identified.
 ✔ Investigate patients who may have gastro-oesophageal 
reflux according to local policies.
 ✔ Consider the addition of prokinetic agents if symp-
toms of GORD increase with an airway clearance 
technique in sitting position. Avoid eating in the hour 
immediately prior to physiotherapy.
What is the prevalence of rhinosinusitis in patients with 
stable bronchiectasis and what are the outcomes of 
treatment?
Recommendations
 ► The evaluation of patients with bronchiectasis should 
include assessment of symptoms of chronic rhinosi-
nusitis (D). (see figure 5)
 ► Patients with bronchiectasis and symptoms of rhinosi-
nusitis should be evaluated and treated according to 
existing evidence-based treatment pathways (D).
should treatment of bronchiectasis be altered in the presence 
of comorbidities?
Recommendations
 ► Consider a trial of inhaled and/or oral corticoster-
oids in patients with bronchiectasis and inflammatory 
bowel disease (D)
 ► Ensure optimal control of asthma and allergies in 
patients with both bronchiectasis and asthma (Grade 
D).
 ► Monitor patients with comorbid COPD and bronchi-
ectasis as they are at higher risk of death (D).
 ► Patients with bronchiectasis and autoimmune condi-
tions should be carefully assessed for autoimmune-re-
lated lung disease and often require long-term 
follow-up in a secondary care setting (D).
 ► Patients with bronchiectasis who require disease modi-
fying antirheumatic drugs (DMARDs) or biologics for 
rheumatoid arthritis should be referred to a chest 
physician for further assessment before treatment is 
started (D).
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how should we monitor bronchiectasis?
Recommendation
 ► All patients with bronchiectasis should undergo 
routine monitoring in order to identify disease 
progression, pathogen emergence and modify treat-
ment where necessary (D).
Good practice points
 ✔ Tailor the frequency of routine monitoring to the pa-
tient’s disease severity (see table 7).
 ✔ Assess patients annually and more frequently in more 
severe disease.
 ✔ Perform pulse oximetry to screen for patients who 
may need blood gas analysis to detect respiratory fail-
ure.
 ✔ A baseline CXR may provide a useful com-
parator in the event of clinical deterioration. 
Is there a role for microbiological sensitivity testing?
Good practice points
 ✔ Antibiotic sensitivity testing can be used to determine 
if resistance develops to either acute or long-term an-
tibiotic treatment.
 ✔ Where possible, treatment should be guided by anti-
biotic sensitivity results but is often empirical based 
on previous sputum bacteriology.
 ✔ Some patients with an infective exacerbation may 
respond to antibiotic treatment despite resistance to 
that drug in vitro. Antibiotics should only be changed 
if there is no clinical response.
 ✔ For those on long-term antibiotic treatment, there 
should be repeat sensitivity testing where there is a 
clinical concern regarding loss of efficacy with ther-
apy.
Is there any evidence of cross-infection with pathogenic 
organisms (conventional bacteria and environmental 
mycobacteria)?
Recommendation
 ► Individual or cohort segregation based on respiratory 
tract microbiology results is not routinely required 
for patients with bronchiectasis (D)
Good practice points
 ✔ Good cross-infection prevention principles should be 
applied: seek advice on local policies.
 ✔ The transmissibility of P. aeruginosa in CF appears 
more common. In the case of shared facilities with 
patients with CF, the cross-infection guidelines for CF 
should prevail.
Research recommendation
Large-scale robust data that confirm or refute the 
transmissibility of key pathogens such as P. aeruginosa 
and non-tuberculous mycobacteria are needed.
Larger multicentre studies with longitudinal assess-
ment of transmissible strains in bronchiectasis are 
needed. Studies are needed for P. aeruginosa and 
non-tuberculous mycobacteria as these are associated 
with poorer outcomes.
specialist versus non-specialist setting
Good practice point
 ✔ Specialist clinics should be considered in patients re-
quiring hospital follow-up.
What are the complications of bronchiectasis?
Good practice points
 ✔ If haemoptysis 10 ml or less over a 24-hour period, 
treat with an appropriate oral antibiotic. If clinical de-
terioration, arrange emergency admission to hospital.
 ✔ Management of major haemoptysis should be multi-
disciplinary with involvement of respiratory physi-
cians, interventional radiology and thoracic surgeons. 
Empirically treat patients with intravenous antibiotic 
therapy, based on their known microbiology, and con-
sider adjunct treatment with tranexamic acid. Bron-
chial artery embolisation is the recommended first-
line treatment if significant haemoptysis persists.
 
Healthcare providers need to use clinical judgement, knowl-
edge and expertise when deciding whether it is appropriate to 
apply recommendations for the management of patients. The 
recommendations presented here are a guide and may not be 
appropriate for use in all situations. The guidance provided 
does not override the responsibility of healthcare profes-
sionals to make decisions appropriate to the circumstances of 
each patient, in consultation with the patient and/or their 
guardian or carer.
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